Sex hormones in serum have been hypothesized to influence the risk of prostate cancer. We performed a collaborative analysis of the existing worldwide epidemiologic data to examine these associations in a uniform manner and to provide more precise estimates of risks.
Prostate cancer is the second most common cancer in men worldwide ( 1 ) , and the only established risk factors for prostate cancer are age, race, and a family history of the disease ( 2 ) . Androgens are required for the normal growth and development of the prostate gland, and high levels of androgens have long been hypothesized to be possible risk factors for prostate cancer ( 3 , 4 ) . Evidence that the development of prostate cancer has a hormonal component comes from a wide range of sources, including the historical observation that most prostate tumors respond to androgen deprivation therapy until they establish an androgen-independent growth mechanism. More recently, results from the Prostate Cancer Prevention Trial ( 5 , 6 ) indicated that inhibition of the conversion of testosterone to the more potent dihydrotestosterone (DHT) by fi nasteride, a 5 ␣ -reductase inhibitor, reduced the occurrence of prostate cancer by approximately 25% during a 7-year follow-up, although the risk of high-grade tumors was higher in the treated group than in the untreated group.
To date, 18 prospective studies have investigated whether differences in circulating levels of sex hormones are related to the risk of prostate cancer ( 7 -27 ) . The results have been somewhat inconsistent, with a number of studies fi nding small associations for some hormones. However, many of the studies individually had limited power.
The Endogenous Hormones and Prostate Cancer Collaborative Group was established to conduct pooled analyses of the original data from studies on the relationships among endogenous sex hormones, insulin-like growth factors (IGFs), and prostate cancer risk. The specifi c aims of the group were 1) to use uniform statistical methods to provide precise estimates of the associations of endogenous hormones and IGFs with prostate cancer risk; 2) to investigate whether the association of risk differs with time between blood collection and diagnosis; 3) to examine the relative risks (RRs) in different tumor subgroups; 4) to identify whether there are interactions among hormone concentrations, IGFs, and risk of prostate cancer; and 5) to examine the cross-sectional relationships between lifestyle factors and concentrations of sex hormones and IGFs. In this analysis, we addressed the fi rst four of these objectives in relation to endogenous sex hormones; analyses of prostate cancer risk in relation to IGFs will be reported elsewhere. concurrent drug use; date of (or age at) diagnosis; stage and grade of the tumor; method of case-patient ascertainment (self-report, record linkage, or unknown); height; weight; waist and hip circumferences; history of prostate disease; family history of prostate cancer; smoking habits; alcohol intake; educational status; marital status; race; serum concentrations of androstenedione, androstanediol glucuronide, dehydroepiandrosterone (DHEA), DHEA sulfate (DHEA-S), total testosterone, DHT, total estradiol, estrone, sex hormone -binding globulin (SHBG), IGF-I, IGF-II, IGF-binding proteins 1, 2, and 3, and PSA at blood collection. Not all of the hormone and SHBG measurements were performed by each study, and investigators were asked to provide whatever measurements were available (for details of the assay methods used by individual studies, see Supplementary Table 2, available online).
Free testosterone and free estradiol were calculated from the reported measured serum concentrations of testosterone or estradiol and SHBG by use of the law of mass action ( 29 ) and by assuming a constant serum albumin concentration of 43g/L. Such calculated results have been found to correlate highly with the free fractions of these hormones measured by equilibrium dialysis ( 30 , 31 ) .
For most studies, data supplied to the collaborative group were identical to those analyzed and published by the original research group. However, in the Northern Sweden Health and Disease Cohort ( 20 ) and the Prostate Testing for Cancer and Treatment (ProtecT) study ( 28 ) , data on additional hormones were available
CONTEXT AND CAVEATS

Prior knowledge
Sex hormones in serum could, hypothetically, influence the risk of prostate cancer.
Study design
Pooled analysis of 18 prospective studies on the association between sex hormone concentrations in serum and the risk of prostate cancer. A total of 3886 men with incident prostate cancer and 6438 control subjects were included in this analysis.
Contribution
No associations were found between the risk of prostate cancer and serum concentrations of testosterone, calculated free testosterone, dihydrotestosterone, dehydroepiandrosterone sulfate, androstenedione, androstanediol glucuronide, estradiol, or calculated free estradiol. A modest inverse association was observed between the risk of prostate cancer and the serum concentration of sex hormone -binding globulin.
Implications
Sex hormones apparently do not influence the risk of prostate cancer.
Limitations
Possible biases could have been introduced because of the long latency associated with prostate cancer, which could result in some control subjects having occult disease. Different laboratory methods were used in different studies to measure sex hormone concentrations in serum. Hormone concentrations were measured in only one sample for each participant.
that were not included in their published reports. The Health Professionals Follow-up Study ( 25 ) provided data on additional case -control sets that had not yet been reported. Finally, the Rancho Bernardo Study ( 8 ) had additional unpublished follow-up data that were contributed to this collaborative analysis.
Data Processing
Some studies ( 7 , 9 -11 , 14 , 16 , 22 ,24, 25 ) had published more than one investigation on the association between endogenous sex hormones and prostate cancer risk, sometimes with different matched casecontrol sets, different laboratory measurements, and different amounts of follow-up. For each study, a dataset was created in which each participant appeared only once. Thus, we treated any participant who appeared as both a control subject and a case patient in the original study datasets as a case patient in this analysis.
For this analysis, matched-set identifi ers were removed and a series of strata (equivalent to matched sets) were generated in which participants in each study were grouped according to age at recruitment (2-year age bands) and date of recruitment (by year) because these matching criteria were common to most studies. The number of strata used in the collaborative analysis was slightly less than the number of matched sets used in the original analyses.
Each study provided data on prostate cancer stage and grade, if available. To provide a common defi nition across studies, if tumor stage information was available, we defi ned a cancer as being advanced if it was tumor -node -metastasis stage T3+/N1+/ M1+ or the equivalent (a tumor extending beyond the prostate capsule with or without lymph node involvement and/or distant metastases) and otherwise we defi ned it as being localized. If tumor grade information was available, we defi ned a cancer as high grade if it had a Gleason sum of at least 7 or the equivalent (ie, moderately to poorly differentiated) and otherwise we defi ned it as low grade.
Statistical Analysis
Partial correlation coefficients were calculated between log-transformed serum hormone concentrations (to normalize the distribution) among control subjects, adjusted for age at blood collection (<50, 50 -59, 60 -69, or ≥ 70 years) and study. For each hormone, men were categorized into fifths of its serum concentrations, with cut points defined by the study-specific fifths of the distribution within control subjects. If a study measured serum hormone concentrations at more than one time point (and possibly with different assay methods), cut points were determined separately for each time point. To assess whether there was evidence of an association between sex hormone concentration and risk of prostate cancer at the upper or lower tails of the distribution, men were categorized into deciles in a similar way.
The main method of analysis was conditional logistic regression that was stratifi ed by study, age at recruitment (2-year age bands), and date of recruitment (single year). To provide a summary measure of risk, a linear trend was calculated by replacing the categorical variable representing the fi fths of the serum hormone concentration with a continuous variable that was scored as 0, 0.25, 0.5, 0.75, and 1. A unit change in this continuous trend variable is equivalent to the relative risk comparing the highest with the lowest fi fth.
For each hormone, heterogeneity in linear trends among studies was assessed with a chi-square test. The chi-square statistic was calculated as the difference between the sum of the model chi-square values for each individual study and the model chi-square value from the all-studies analysis. This method is equivalent to an overall test of whether the study-specifi c relative risks are statis tically signifi cantly different from the overall relative risk. Heterogeneity among studies was also quantifi ed by calculating the H and I 2 statistics ( 32 ) . The H statistic is a measure of the amount of heterogeneity between studies, with H = 1.0 indicating homogeneity and with heterogeneity increasing as H becomes greater than 1.0. The I 2 statistic can be interpreted as the proportion of variation in study-specifi c estimates due to heterogeneity. Assay methods that include a purifi cation or extraction step (ie, assays for testosterone, DHT, androstanediol glucuronide, and estradiol) may be more accurate than those that do not. Therefore, a chi-square test for heterogeneity in risk estimates between these methods was calculated.
The possible infl uences of participant characteristics on the associations between the concentration of sex hormones and prostate cancer risk were examined by adjusting the relevant conditional logistic regression models for body mass index (<22.5, 22.5 -24.9, 25.0 -27.4, 27.5 -29.9, or ≥ 30 kg/m 2 or not known), marital status (married or cohabiting, not married or cohabiting, or not known), educational status (did not attend college or university, attended college or university, or not known), smoking (never, previous, current, or not known), and alcohol consumption (<10 or ≥ 10 g/day or not known).
To test whether the linear-trend relative risk estimates for each sex hormone varied according to case patient characteristics, a series of subsets for each characteristic were estimated: stage at diagnosis (localized or advanced), grade at diagnosis (low or high), year of diagnosis (pre-1990, 1990 -1994, or 1995 onward; these year cutoffs were chosen in an attempt to refl ect differences in the use of the PSA test for cancer detection), age at diagnosis (<60, 60 -69, or ≥ 70 years), and time between blood collection and diagnosis (<3, 3 -6, or ≥ 7 years). Case patients were excluded from the analyses of stage and grade at diagnosis if the relevant information on stage or grade was not available. For each of these case patient characteristics, the heterogeneity test was calculated as the difference between the sum of the model chi-square values from each of the subset models and the overall model chi-square value (by use of data from the same case patients that were used in the subsets). This method is equivalent to performing a contrast test of whether, for each of the case patient characteristics, the estimated regression coeffi cients from the subsets were statistically signifi cantly different from each other. To assess whether the relative risk estimate of the linear trend for each sex hormone varied according to PSA level at recruitment (<2 ng/mL or ≥ 2 ng/mL; grouping participants according to their probability of having a latent prostate cancer at recruitment), an interaction term was entered into the conditional logistic regression model for each hormone and the statistical signifi cance of the interaction term was tested with a likelihood ratio test. The same method was used to examine whether there was an interaction among linear trends for serum concentrations of two (or more) sex hormones or among linear trends for serum concentrations of sex hormones and IGF-I concentration and prostate cancer risk.
Statistical signifi cance was set at the 5% level. All statistical tests were two-sided. All statistical analyses were performed with Stata version 9.0 (Stata Corp., College Station, TX).
Results
Data on serum testosterone concentration were available for 3886 case patients with prostate cancer and 6438 control subjects from 18 prospective studies. A similar amount of data was available for SHBG, enabling the concentration of free testosterone to be cal culated for 3550 case patients and 5815 control subjects. Data on estradiol were available for 2186 case patients and 3039 control subjects. Data for androstanediol glucuronide were available for 2453 case patients and 3035 control subjects. Individual-level data for DHT, DHEA-S, and androstenedione were available from at least 1000 case patients.
Among the control subjects, the mean age at recruitment ranged from 46 to 72 years and the date of study recruitment ranged from 1961 through 2001 ( Table 1 ) . Mean body mass index ranged from 22.4 to 28.2 kg/m 2 . Between 4% and 37% of control subjects smoked [except in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study ( 17 ) and the Carotene and Retinol Effi cacy Trial ( 21 ) , which recruited either all smokers or an enriched sample of smokers, respectively], and the mean consumption of alcohol ranged from 11.5 through 21.7 g/day. There was considerable variation in the time between blood collection and diagnosis: in the ProtecT study ( 28 ) , all case patients were diagnosed within 3 years of recruitment, but in studies from the Janus Serum Bank in Norway ( 22 ) , more than 90% of case patients were diagnosed 7 or more years after recruitment ( Table 2 ). Most case patients were diagnosed when older than 60 years, and many studies consisted of case patients who were older than 70 years at diagnosis. Among case patients with available data, 60% -70% had localized disease and a similar proportion had low-grade disease. We next determined the median serum concentration and its interquartile range for each hormone by study and case -control status ( Table 3 ) . Although the absolute serum concentrations of sex hormones varied among studies, the concentrations for each hormone between case patients and control subjects were very similar within most studies. Within each study, the extent of betweensubject variation in hormone levels was similar, with the interquartile range representing increased hormone concentrations of between 50% and 100%.
Serum concentrations of testosterone, free testosterone, and DHT were positively correlated with each other (all r > 0.29) but were not correlated with the serum concentration of DHEA-S (all r < 0.12; Table 4 ). The serum concentration of androstanediol glucuronide was weakly correlated with that of the other androgens ( r of between 0.1 and 0.3). Serum concentrations of the androgens (except for DHEA-S) were moderately correlated with that of estradiol ( r of between 0.2 and 0.3), but the serum concentration of free estradiol was correlated only with that of free testosterone ( r = 0.31). The serum concentration of SHBG was positively correlated with those of testosterone ( r = 0.51) and DHT ( r = 0.33) but was negatively correlated with that of free testosterone ( r = -0.15) and, to a greater extent, with that of free estradiol ( r = -0.42). PSA levels at recruitment were not correlated with concentrations of the androgens and estradiol, except for a weak positive correlation with the concentration of free testosterone ( r = 0.11). The concentration of IGF-I was weakly negatively correlated with the concentration of SHBG ( r = Ϫ 0.12) but not correlated with concentrations of the sex hormones.
Associations Between Serum Sex Hormone Concentrations and Prostate Cancer Risk
There were no statistically significant associations between serum concentrations of any of the androgens or estrogen and risk of prostate cancer, comparing the highest fifth with the lowest fifth (eg, for testosterone, RR = 0.94, 95% confidence interval [CI] = 0.82 to 1.07 and, for free testosterone, RR = 1.11, 95% CI = 0.96 to 1.27) ( Fig. 1 ) . Although comparing the highest with the lowest fifth of DHT concentrations and risk of prostate cancer indicated a possible inverse association (RR = 0.86, 95% CI = 0.66 to 1.11), there was no evidence of a dose -response relationship. There was also no evidence of an association of risk of prostate cancer with concentrations of androstanediol glucuronide, androstenedione, DHEA-S, estradiol, or free estradiol ( Fig. 1 ) . SHBG was statistically significantly and inversely related to prostate cancer risk (RR = 0.86, 95% CI = 0.75 to 0.98, comparing the highest fifth with the lowest fifth), and evidence of a statistically significant doseresponse relationship was also found ( P trend = .01). When we categorized the concentrations of each hormone into deciles, we found no evidence of an association between prostate cancer risk and either very high or very low serum concentrations of sex hormones (results not shown).
There was no evidence of heterogeneity between studies for the estimates of the linear trend for any serum hormone concentration and prostate cancer risk (all P >.10 and only two of the nine I 2 estimates were >5%, indicating that there was very little evidence of heterogeneity in linear trends between studies; Supplementary Figs. 1 -9, available online). There was no statistically signifi cant heterogeneity between the estimates of linear trend for concentrations of testosterone, DHT, androstanediol glucuronide, and estradiol and prostate cancer risk according to whether or not the assays included an extraction or purifi cation step (all P >.10).
Adjustment for Potential Confounders
The associations between concentrations of serum sex hormones and risk of prostate cancer were examined before and after adjustment for the following characteristics: body mass index, marital status, educational status, smoking, and alcohol consumption. Age was dealt with through stratification. Adjustment for these variables, either individually or mutually, made no appreciable difference to the associations between serum hormone concentrations and risk of prostate cancer (results not shown).
Subgroup Analyses by Patient Characteristics
There was no statistically significant heterogeneity for either stage or grade of prostate cancer at diagnosis in associations between prostate cancer risk and serum concentrations of testosterone, free testosterone, androstanediol glucuronide, androstenedione, estradiol, free estradiol, and SHBG ( Fig. 2 ) . However, although DHT concentration was not associated with the risk of localized (RR = 0.72, 95% CI = 0.51 to 1.01) or advanced (RR = 1.47, 95% CI = 0.86 to 2.50) prostate cancer in linear trend analyses, these associations were statistically significantly different from each other ( P for heterogeneity = .03) ( Fig. 2, A ) . Risks of localized vs advanced prostate cancer associated with serum concentration of DHEA-S were also statistically significantly different from each other ( P for heterogeneity = .04); the linear trend estimate for DHEA-S serum concentration was not associated with the risk of localized disease (RR = 1.00, 95% CI = 0.75 to 1.33) but was statistically significantly associated with an increased risk of advanced disease (RR = 2.00, 95% CI = 1.10 to 3.65) ( Fig. 2, A ) . There was no variation in the associations between serum concentrations of any of the sex hormones and prostate cancer risk for time between blood collection and diagnosis, year of diagnosis, age at diagnosis, or PSA level at recruitment ( Figs. 3 and 4 ) . Subgroup results remained unchanged after adjustment for potential confounding variables, including body mass index (results not shown). Analyses that jointly classified tumors by both stage and grade did not detect evidence of additional heterogeneity in risk for any subgroup compared with the differences observed in the analyses of stage and grade (results not shown).
Relationship Between Serum Concentrations of Multiple Sex Hormone and Prostate Cancer Risk
The joint relationships between concentrations of two or more hormones and the risk of prostate cancer were examined. For the combination of testosterone and estradiol and the combination of free testosterone and free estradiol (hence simultaneously adjusting for SHBG), the estimated linear trend from the univariate model was virtually unchanged when serum concentrations of either combination of hormones were included in a joint model (both P interaction >.10) ( Table 5 ). Simultaneous adjustment for serum concentrations of free testosterone, free estradiol, androstanediol glucuronide, and DHT or that of androstenedione or of DHEA-S did not alter the results obtained from univariate analyses of these sex hormones ( Table 5 ) . We next considered mutual adjustment for SHBG and IGF-I on the basis of their biological relationship ( Table 5 ) . When the serum concentration of IGF-I was included in the statistical model as an additional variable, associations between the risks for prostate cancer and serum concentration of SHBG or IGF-I were essentially unchanged, but the association between the serum concentration of SHBG and prostate cancer risk became non -statistically signifi cant after adjustment for IGF-I (before, RR = 0.83, 95% CI = 0.71 to 0.97, P = .02; and after, RR = 0.88, 95% CI = 0.75 to 1.04, P = .12). Mutual adjustment of concentrations of testosterone, estradiol, free testosterone, and free estradiol for IGF-I * Data are partial correlation coefficients of log-transformed hormone concentrations that were adjusted for age at blood collection (in four groups) and study. n = the number of control subjects with a measurement for that hormone; DHT = dihydrotestosterone; DHEA-S = dehydroepiandrosterone sulfate; SHBG = sex hormone -binding globulin; PSA = prostate-specific antigen; IGF-I = insulin-like growth factor I.
concentration did not change any of the results appreciably (results not shown).
Discussion
The main finding of this pooled analysis of approximately 3900 patients with prostate cancer and 6500 control subjects was that prediagnostic serum concentrations of testosterone, free testosterone, DHT, androstanediol glucuronide, DHEA-S, androstenedione, estradiol, or free estradiol were not associated with the risk of subsequent prostate cancer. There was no heterogeneity in the estimated trends among the studies for any of the hormones, and adjustment for potential confounders made little difference to the risk estimates. This collaboration was successful in collecting more than 95% of the identifi ed prospective worldwide data on endogenous sex hormones and prostate cancer risk. Through this collaborative approach, we were also able to obtain additional, as yet unpublished, data, although it is possible that we were unaware of other unpublished studies.
There have been many reviews and commentaries on the role of sex hormones in the development of prostate cancer, which hypothesize that high circulating levels of androgens are associated with an increased risk ( 3 , 4 , 33 -37 ) . The fi ndings from this pooled het) is to assess whether the relative risk estimates for each characteristic are different from each other. The P value was two-sided for statistical signifi cance of the chi-square heterogeneity statistic. RR = relative risk; CI = confi dence interval; DHT = dihydrotestosterone; Adiol-G = androstanediol glucuronide; DHEA-S = dehydroepiandrosterone sulfate; SHBG = sex hormone -binding globulin.
analysis of the worldwide data, however, showed no association between prostate cancer risk and serum concentrations of testosterone, free testosterone, DHT, androstenedione, or DHEA-S. Testosterone is converted to the more androgenic DHT (by the action of 5 ␣ -reductase) within the prostate, but the proportion of prostate-produced DHT that reaches the serum has not been determined. Thus, the relationship between the concentration of DHT in serum and in the prostate is unclear and could explain the lack of an association between serum levels and prostate cancer risk. However, we did observe that higher concentrations of DHT were associated with a non -statistically signifi cant increase in the risk of advanced disease and a non -statistically signifi cant decrease in the risk of localized disease. Furthermore, we cannot rule out chance as an explanation for the heterogeneity observed because of the large numbers of statistical tests performed.
The serum DHT concentration refl ects not only the activity of 5 ␣ -reductase type 2 within the prostate but also that of 5 ␣ -reductase type 1 in the skin and, to a lesser extent, the liver ( 38 ) . An alternative serum marker of 5 ␣ -reductase activity is the concentration of androstanediol glucuronide, a terminal metabolite of DHT. However, like the serum concentration of DHT, the concentration of serum androstanediol glucuronide also refl ects the activities of both 5 ␣ -reductase types 1 and 2. However, administration of a selective 5 ␣ -reductase type 2 inhibitor leads to an approximate 85% reduction in the concentration of serum androstanediol glucuronide and a 70% reduction in the concentration of serum DHT. These results indicate that intraprostatic androgen activity may be more closely related to the serum concentration of androstanediol glucuronide than to serum DHT concentration ( 39 , 40 ) . Assays of serum androstanediol glucuronide usually measure only androstanediol 17-glucuronide, one of the two isomers of this metabolite. Because this isomer is the predominant isomer in the circulation, representing more than 80% of the total circulating concentration of androstanediol glucuronide ( 41 -43 ) , androstanediol 17-glucuronide may be a useful proxy for total serum concentration of androstanediol glucuronide. If the concentration of serum androstanediol glucuronide is a valid marker of intraprostatic androgen activity, the fi ndings of this collaborative analysis do not support the hypothesis that such activity is strongly related to the risk of prostate cancer. However, without data directly comparing serum concentrations of these hormones with intraprostatic concentrations, any biological interpretation must be viewed with caution.
The fi ndings from this collaborative study indicate that endogenous estrogen concentrations are not related to prostate cancer risk. It has been proposed ( 13 ) that a combination of estrogens and androgens may be more strongly associated with the risk of prostate cancer than either estrogen or androgen alone. However, the results from this pooled analysis show that mutual adjustment for serum concentrations of free testosterone, free estradiol, and androstanediol glucuronide did not change the estimated trends compared with analyses of the individual hormones. Further, there was no evidence of interactions between concentrations of any of the hormones considered and risk of prostate cancer.
This study found a modest inverse association between serum SHBG concentration and prostate cancer risk, with a relative risk reduction of 14% (95% CI = 2% to 25%) when the highest fi fth was compared with the lowest fi fth. Further adjustment for body mass index, which was correlated with SHBG level ( r = Ϫ 0.27 in this study), did not appreciably alter this risk estimate. SHBG is a major determinant of the serum concentrations of free testosterone and estradiol, which regulate steroid hormone production through a negative feedback loop ( 44 ) . Insulin and, to a lesser extent, IGF-I inhibit SHBG production ( 33 ) . Most studies did not measure the concentration of insulin, but we observed a negative correlation between IGF-I and SHBG serum concentrations ( r = Ϫ 0.12). After adjustment of SHBG for IGF-I serum concentrations, the estimated trend was only slightly attenuated toward the null but was no longer statistically signifi cant. Although this slight attenuation could be a consequence of the mutual adjustment and errors in the measurement of IGF-I, it is also possible that the inverse association observed between SHBG serum concentration and prostate cancer risk is a consequence of the negative relationship between concentrations of SHBG and IGF-I, which itself is positively associated with risk (The Endogenous Hormones and Prostate Cancer Collaborative Group, unpublished results).
One of the aims of this analysis was to examine whether the associations of serum concentrations of sex hormones with risk of prostate cancer varied according to the clinical characteristics of the disease. Such questions are important because there have been substantial changes in prostate cancer detection since the late 1980s, when the introduction of PSA testing led to a sharp increase in incidence rates, with many more localized cancers being detected than advanced cancers ( 45 ) . The combination of an increasing proportion of early, often asymptomatic, disease and a decreasing proportion of advanced cancers at diagnosis can introduce diffi culties in the interpretation of results from individual studies ( 46 ) . The introduction of PSA testing has further complicated the situation by increasing the lead time (ie, the number of years earlier the tumor is detected as a result of testing) by a period that was estimated to be as long as 12 years in men aged 55 years ( 47 , 48 ) . Moreover, approximately 30% of early-stage PSA-detected prostate cancers may be the result of overdetection; that is, if left undetected, these cancers would never progress to clinical disease ( 47 ) . It has been shown that up to 80% of men older than 80 years at autopsy have small foci of incidental prostate cancer ( 49 ) . Unfortunately, we did not have detailed information on each participant's PSA screening history or on which of the cancers were detected by PSA screening. Therefore, we attempted to address these concerns in various subgroup analyses. First, we examined the consistency of the associations of hormone concentrations with risk . The length of the horizontal line through the square indicates the 95% confi dence interval. The chi-square statistic for heterogeneity ( χ 2 2 and χ 1 2 het) is to assess whether the relative risk estimates for each characteristic are different from each other. The P value was two-sided for statistical signifi cance of the chi-square heterogeneity statistic. RR = relative risk; CI = confi dence interval; DHT = dihydrotestosterone; Adiol-G = androstanediol glucuronide; DHEA-S = dehydroepiandrosterone sulfate; SHBG = sex hormone -binding globulin.
of prostate cancer by stage and grade of the disease at diagnosis. Although there were some small differences in the estimated risks, these differences could be due to chance because of repeated statistical testing. In addition, there are no clear biological mechanisms underlying such associations. Second, we found no statistically signifi cant heterogeneity in the risks of prostate cancer according to the age at diagnosis, time between recruitment and diagnosis, year of diagnosis, or the PSA level at recruitment, which suggests that the introduction of PSA testing and differences in its use in various populations may not have unduly infl uenced the associations.
Our study had several limitations in common with most prospective studies of prostate cancer risk. There are possible biases that can be introduced due to the long latency associated with the disease, which would result in some control subjects having occult disease. However, in a large study in which the relationship between the exposure and disease is at least moderate, it is unlikely that associations would be missed as a result of some control subjects having occult disease ( 46 ) . In this pooled analysis with many case patients and with no variation in the estimated risks according to time between blood collection and diagnosis or age at diagnosis, it seems unlikely that such misclassifi cation would have had a major effect.
A further limitation is that many different laboratory methods were used in the different studies to measure serum concentrations of sex hormones, which may be responsible for much of the variation in hormone concentrations among studies (for detailed descriptions of laboratory methods, see Supplementary Table 2 , available online). However, our primary method of analysis allowed for this problem by defi ning within-study fi fths of hormone concentration and by pooling study-specifi c estimates of relative risk. This method assumes that the fi fths are comparable among studies; if this assumption was not valid, estimated relative risks could be biased. However, because we found no evidence of heterogeneity among studies for the association of sex hormone concentration and prostate cancer risk and have no reason to expect that the distributions of hormone concentrations would be very different among the men in the different studies, this assumption appears reasonable.
Another possible limitation is that this pooled analysis relied on the measurement of serum hormone levels in only one sample at only one time. These single measurements provide an imperfect estimate of a man's usual hormonal status and can be infl uenced both by within-person errors and analytic errors. Both types of error are likely to lead to attenuation of the relationship between hormone concentration and risk ( 50 ) . Therefore, such attenuation could have masked a moderate relative risk in our analysis, although because most hormones showed no statistical evidence of a dose -response relationship, the combined effect of both withinperson and analytic error would have to have been substantial. Although a single measurement of hormone concentration can reliably refl ect average exposure over a short time interval ( 25 , 51 ) , it is not clear whether one measurement also adequately refl ects a lifetime exposure. Little is known about whether hormonal status early in life, such as during adolescence ( 52 ) or in utero ( 53 ) , is important for the subsequent development of prostate cancer.
In summary, the results of this collaborative analysis of the existing worldwide data on the associations between endogenous hormone concentrations and prostate cancer risk indicate that circulating concentrations of androgens or estradiol do not appear to be associated with the risk of prostate cancer.
